Phase 4 N=20 Angiotensin II Blockade and Inflammation in Obesity
Overweight · Obese · Prehypertension
Primary: Insulin Sensitivity by Intravenous Glucose Tolerance Testing (Change Over Time) — 0.253; -0.804 mu/L/min
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=21 Comparative Urine Proteomic Studies of Overactive Bladder in Humans
Overactive Bladder
Primary: Bladder Diary to Assess Urinary Frequency at Baseline and at End of 6-week Treatment — 12.32; 10.79 urinations/day — p=0.19
Phase 1 N=56 Effect of Footwear on the Clinical, Functional, and Biomechanical Aspects in Elderly Women With Knee Osteoarthritis (OA)
Knee Osteoarthritis
Primary: Western Ontario and McMaster Universities (WOMAC) Pain Subscale — 9.2; 10.0; 4.5; 6.6 score — p=0.006
Phase 1 N=50 Safety and Tolerability of Ascending Intravenous Doses of PF-05231023 In Adult Subjects With Type 2 Diabetes
Diabetes Mellitus, Type 2
Primary: Number of Participants With Abnormal Physical Examination Findings
Phase 2 N=10 A Study to Investigate the Tolerability and Effect of Three Single-dose Regimens of BIA 9-1067
Parkinson's Disease
Primary: Cmax - Maximum Plasma Concentration Day 3 — 2103; 2112; 2366; 2657 ng/ml
N/A N=406 Preparedness Study - HPV Vaccine
Sexual Transmission of Infection
Primary: Human Papillomavirus (HPV) Rate — 143; 136; 106; 113 participants
Phase 2 N=20 Trial Of Double Umbilical Cord Blood Transplantation
Hematological Malignancies
Primary: Percentage of Participants Alive at 1 Year After Transplant — 40 percentage of participants
Phase 2 N=341 Adult Attention Deficit Hyperactivity Disorder
Adult Attention Deficit Hyperactivity Disorder
Primary: Change From Baseline at Week 4 in ADHD Symptoms Measured With the ADHD Rating Scale Version IV With Adult Prompts (ADHD RS IV) — -12.38; -13.88; -9.7 units on a scale…
Phase 3 N=117 Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine, Fluarix/Influsplit Tetra® (2013/2014 Season), in Adults 18 Years of Age and Older
Influenza
Primary: Anti-HI Antibody Titers Against 4 Strains of Influenza Disease — 29.8; 14.9; 13.1; 13.5 Titers
N/A N=49 A Retrospective Study of Real World Treatment Outcomes of Patients With Chronic Hepatitis C
Hepatitis C, Chronic
Primary: Sustained Virological Response (SVR): Percentage of Participants Who Were HCV Seronegative at 6 Months After Completing Therapy — 59.5; 58.3 percentage of participants
Phase 1 N=40 Comparative Bioavailability Study of Two Different Sources of Eslicarbazepine Acetate
Epilepsy
Primary: Cmax - Maximum Plasma Concentration — 6461; 13183; 6547; 12988 ng/ml
N/A N=20 Dalfampridine and Gait in Spinocerebellar Ataxias
Spinocerebellar Ataxias Type 1 · Spinocerebellar Ataxias Type 2 · Spinocerebellar Ataxias Type 3
Primary: Change in Timed 25 Feet Walking Test (T25FW) — 23.7; 24.4; -1.1; -0.3 second — p=>0.05
Phase 1 N=17 An Open-label, Multiple-dose, Single-centre Study, Investigating the Pharmacokinetics of BIA 2-093
Epilepsy
Primary: Area Under the Plasma Concentration Versus Time Curve, AUC(0-tlast). — 954.891; 49.750; 240188.369; 234750.429 h·ng/mL
Phase 3 N=60 A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) in the Treatment of Acute Pain From Bunionectomy Compared With Placebo
Hallux Valgus
Primary: Sum of Pain Intensity Difference (SPID) Over 48 Hours — 50.8; 168.4; 194.9 units on a scale — p=0.006
N/A N=334 Independent Predictors of Mortality in Polytrauma Patients
Multiple Trauma
Primary: Death — 52 participants — p=< 0.001